Evaluation of adverse events of bamlanivimab, bamlanivimab/etesevimab used for COVID-19 based on FAERS database
Author:
Affiliation:
1. School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, China
2. School of Pharmaceutical Sciences, Zhengzhou Railway Vocational and Technical College, Zhengzhou, Henan, China
Publisher
Informa UK Limited
Subject
Pharmacology (medical),General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/14740338.2023.2130888
Reference65 articles.
1. WHO Coronavirus (COVID-19) Dashboard. World Health Organization. [cited 2022 Mar 6]. Available from: https://covid19.who.int./
2. Symptoms of COVID-19. Centers for disease control and prevention. [cited 2022 Mar 6]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html#seek-medical-attention
3. Questions and answers on COVID-19: Medical information. European Centre for Disease Prevention and Control. [cited 2022 Mar 6]. Available from: https://www.ecdc.europa.eu/en/covid-19/questions-answers/questions-answers-medical-info
4. A Case of Vasculitis-Like Skin Eruption Associated With COVID-19
5. Olfactory and gustatory function impairment in COVID ‐19 patients: Italian objective multicenter‐study
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Safety evaluation of ceftazidime/avibactam based on FAERS database;Infection;2024-06-06
2. Non-coding RNAs expression in SARS-CoV-2 infection: pathogenesis, clinical significance, and therapeutic targets;Signal Transduction and Targeted Therapy;2023-12-06
3. Development of a neutralization monoclonal antibody with a broad neutralizing effect against SARS-CoV-2 variants;Virology Journal;2023-12-01
4. Effects of bamlanivimab alone or in combination with etesevimab on subsequent hospitalization and mortality in outpatients with COVID-19: a systematic review and meta-analysis;PeerJ;2023-05-08
5. A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database;Expert Opinion on Drug Metabolism & Toxicology;2023-04-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3